News

reMYND receives a grant of almost 1 million EUR from IWT
10-12-2008

reMYND receives a grant of almost 1 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).

Visit the IWT website

reMYND's Lead Alzheimer drug demonstrates neuroprotection
15-11-2008

reMYND's Lead Alzheimer drug demonstrates neuroprotection in 2 transgenic animal models of TAU and Amyloid bèta pathology.

reMYND licenses highly innovative transgenic mouse models
20-08-2008

reMYND licenses highly innovative transgenic mouse models of Alzheimer's Disease TAU and Amyloid pathology from the University of Leuven.

Visit the University of Leuven website

reMYND installs world-class scientific advisory board
25-06-2008

reMYND installs world-class scientific advisory board with Parkinson's and Alzheimer's Disease experts.

Lead product for treating Parkinson's Disease demonstrates efficacy
15-03-2008

Lead product for treating Parkinson's Disease demonstrates efficacy in 3 different animal models of Parkinson's Disease: a chemically-induced model and 2 different transgenic α-synuclein mouse models.